Abstract
Brain atrophy caused by neuronal loss is a prominent pathological feature of Alzheimers disease (AD). Amyloid (A ), the major component of senile plaques, is considered to play a central role in neuronal cell death. In addition to removal of the toxic Aβ , direct suppression of neuronal loss is an essential part of AD treatment; however, no such neuroprotective therapies have been developed. Excess amount of Aβ evokes multiple cytotoxic mechanisms, involving increase of the intracellular Ca2+ level, oxidative stress, and receptor-mediated activation of cell-death cascades. Such diversity in cytotoxic mechanisms induced by Aβ clearly indicates a complex nature of the AD-related neuronal cell death. We have identified a 24-residue peptide, Humanin (HN), which suppresses in vitro neuronal cell death caused by all AD-related insults, including Aβ , so far tested. The anti-AD effect of HN has been further confirmed in vivo using mice with Aβ -induced amnesia. Altogether, such potent neuroprotective activity of HN against AD-relevant cytotoxicity both in vitro and in vivo suggests the potential clinical applications of HN in novel AD therapies aimed at controlling neuronal death.
Keywords: Alzheimer's disease, neuronal death, amyloid, amyloid precursor protein (APP), presenilin (PS), Humanin (HN), neuroprotection
Current Neuropharmacology
Title: Neuronal Cell Death in Alzheimers Disease and a Neuroprotective Factor, Humanin
Volume: 4 Issue: 2
Author(s): Takako Niikura, Hirohisa Tajima and Yoshiko Kita
Affiliation:
Keywords: Alzheimer's disease, neuronal death, amyloid, amyloid precursor protein (APP), presenilin (PS), Humanin (HN), neuroprotection
Abstract: Brain atrophy caused by neuronal loss is a prominent pathological feature of Alzheimers disease (AD). Amyloid (A ), the major component of senile plaques, is considered to play a central role in neuronal cell death. In addition to removal of the toxic Aβ , direct suppression of neuronal loss is an essential part of AD treatment; however, no such neuroprotective therapies have been developed. Excess amount of Aβ evokes multiple cytotoxic mechanisms, involving increase of the intracellular Ca2+ level, oxidative stress, and receptor-mediated activation of cell-death cascades. Such diversity in cytotoxic mechanisms induced by Aβ clearly indicates a complex nature of the AD-related neuronal cell death. We have identified a 24-residue peptide, Humanin (HN), which suppresses in vitro neuronal cell death caused by all AD-related insults, including Aβ , so far tested. The anti-AD effect of HN has been further confirmed in vivo using mice with Aβ -induced amnesia. Altogether, such potent neuroprotective activity of HN against AD-relevant cytotoxicity both in vitro and in vivo suggests the potential clinical applications of HN in novel AD therapies aimed at controlling neuronal death.
Export Options
About this article
Cite this article as:
Niikura Takako, Tajima Hirohisa and Kita Yoshiko, Neuronal Cell Death in Alzheimers Disease and a Neuroprotective Factor, Humanin, Current Neuropharmacology 2006; 4 (2) . https://dx.doi.org/10.2174/157015906776359577
DOI https://dx.doi.org/10.2174/157015906776359577 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Neuroprotective and Preventative Effects of Molecular Hydrogen
Current Pharmaceutical Design Kinin Receptors in Vascular Biology and Pathology
Current Vascular Pharmacology Comprehensive Profiling of Protein Ubiquitination for Drug Discovery
Current Pharmaceutical Design Etanercept Improves Cognitive Performance and Increases eNOS and BDNF Expression During Experimental Vascular Dementia in Streptozotocin- induced Diabetes
Current Neurovascular Research Mucopolysaccharidosis Type II (Hunter Syndrome): Clinical Picture and Treatment
Current Pharmaceutical Biotechnology Conventional and Non-Conventional Targets of Natural Products in the Management of Diabetes Mellitus and Associated Complications
Current Medicinal Chemistry Pilot Randomized Controlled Study of a Histamine Receptor Inverse Agonist in the Symptomatic Treatment of AD
Current Alzheimer Research Can Environmentally Relevant Levels of Aluminium Promote the Onset and Progression of Neurodegenerative Diseases?
Current Inorganic Chemistry (Discontinued) The Therapeutical Potential of Alpha-Synuclein Antiaggregatory Agents for Dementia with Lewy Bodies
Current Medicinal Chemistry Long Non-coding RNA MALAT1 Inhibits Neuron Apoptosis and Neuroinflammation While Stimulates Neurite Outgrowth and Its Correlation With MiR-125b Mediates PTGS2, CDK5 and FOXQ1 in Alzheimer's Disease
Current Alzheimer Research Lower Frequency of co-Morbid Medical Disorders Related to Poor Impulse Control in Parkinson’s than Alzheimer’s Disease
Current Aging Science Substance Abuse, HIV-1 and Hepatitis
Current HIV Research Minocycline and Cytoprotection: Shedding New Light on a Shadowy Controversy
Current Drug Delivery Disrupting Self-Assembly and Toxicity of Amyloidogenic Protein Oligomers by “ Molecular Tweezers” - from the Test Tube to Animal Models
Current Pharmaceutical Design Tetracyclic Triterpenoids in Herbal Medicines and their Activities in Diabetes and its Complications
Current Topics in Medicinal Chemistry Central Nervous System Acting Drugs in Treatment of Migraine Headache
Central Nervous System Agents in Medicinal Chemistry Restless Legs Syndrome/Willis-Ekbom Disease and Periodic Limb Movements: A Comprehensive Review of Epidemiology, Pathophysiology, Diagnosis and Treatment Considerations
Current Rheumatology Reviews Could Resveratrol be a Useful Drug for the Treatment of Malignant Hemopathies?
Recent Patents on Anti-Cancer Drug Discovery Editorial (Thematic Issue: Treating Major Age-Related Diseases in Older and Oldest Old Patients)
Current Pharmaceutical Design Characterization of the Effect of a Novel γ-secretase Modulator on Aβ: A Clinically Translatable Model
Current Pharmaceutical Design